Replies to post #154071 on Biotech Values

[mcbio]

In the trial that pfizer did against Humira, Humira had a 39 percent acr20 response

In this trial Humira's acr20 reponse was 59 percent they highest it ever reached in a clinical trial, so there was something else that was going on

Always a ton of caveats in trying to compare patient populations across different trials. Maybe it's an entirely different patient population here.

The way azn and rigel are positioning the drug is that it has the best response in protecting bone loss in RA. That is a meaningful endpoint and if it succeeds that would be a meaningful claim in the market place

That still needs to be proven I think and I would still question how well it will compete with inferior ACR scores.

[rkrw]

47% for Humira.